{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:36:53Z","timestamp":1787726213787,"version":"build-2784847793"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s00417-025-06878-7","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T22:58:26Z","timestamp":1750978706000},"page":"2693-2707","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Switching to faricimab after prior anti-vascular endothelial growth factor therapy for persistent diabetic macular edema: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"263","author":[{"given":"Ali","family":"Tahmasebi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazanin","family":"Ebrahimiadib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadreza","family":"Niyousha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8296-0918","authenticated-orcid":false,"given":"Narges","family":"Hassanpoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"issue":"12","key":"6878_CR1","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1136\/bjo.2008.144550","volume":"92","author":"M O\u2019Doherty","year":"2008","unstructured":"O\u2019Doherty M, Dooley I, Hickey-Dwyer M (2008) Interventions for diabetic macular oedema: a systematic review of the literature. Br J Ophthalmol 92(12):1581\u20131590","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"6878_CR2","doi-asserted-by":"publisher","first-page":"364","DOI":"10.4093\/dmj.2018.0182","volume":"42","author":"S Kusuhara","year":"2018","unstructured":"Kusuhara S, Fukushima Y, Ogura S, Inoue N, Uemura A (2018) Pathophysiology of diabetic retinopathy: the old and the new. Diabetes Metab J 42(5):364\u2013376","journal-title":"Diabetes Metab J"},{"issue":"3","key":"6878_CR3","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1001\/jamaophthalmol.2015.5346","volume":"134","author":"SB Bressler","year":"2016","unstructured":"Bressler SB, Ayala AR, Bressler NM, Melia M, Qin H, Ferris FL 3rd et al (2016) Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment. JAMA Ophthalmol 134(3):278\u2013285","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"6878_CR4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3928\/23258160-20200228-03","volume":"51","author":"N Ebrahimiadib","year":"2020","unstructured":"Ebrahimiadib N, Lashay A, Riazi-Esfahani H, Jamali S, Khodabandeh A, Zarei M et al (2020) Intravitreal ziv-aflibercept in patients with diabetic macular edema refractory to intravitreal bevacizumab. Ophthalmic Surg Lasers Imaging Retina 51(3):145\u2013151","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"10326","key":"6878_CR5","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C et al (2022) Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet 399(10326):729\u2013740","journal-title":"Lancet"},{"issue":"8","key":"6878_CR6","doi-asserted-by":"publisher","first-page":"e70459","DOI":"10.1371\/journal.pone.0070459","volume":"8","author":"AV Benest","year":"2013","unstructured":"Benest AV, Kruse K, Savant S, Thomas M, Laib AM, Loos EK et al (2013) Angiopoietin-2 is critical for cytokine-induced vascular leakage. PLoS One 8(8):e70459","journal-title":"PLoS One"},{"key":"6878_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ajo.2016.04.017","volume":"168","author":"PA Campochiaro","year":"2016","unstructured":"Campochiaro PA, Hafiz G, Mir TA, Scott AW, Zimmer-Galler I, Shah SM et al (2016) Pro-permeability factors in diabetic macular edema; the diabetic macular edema treated with ozurdex trial. Am J Ophthalmol 168:13\u201323","journal-title":"Am J Ophthalmol"},{"issue":"10326","key":"6878_CR8","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","volume":"399","author":"CC Wykoff","year":"2022","unstructured":"Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z et al (2022) Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet 399(10326):741\u2013755","journal-title":"Lancet"},{"issue":"9","key":"6878_CR9","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1136\/bjo-2023-324394","volume":"108","author":"AF Durrani","year":"2024","unstructured":"Durrani AF, Momenaei B, Wakabayashi T, Vemula S, Pandit SA, Hsu J et al (2024) Conversion to faricimab after prior anti-vascular endothelial growth factor therapy for persistent diabetic macular oedema. Br J Ophthalmol 108(9):1257\u20131262","journal-title":"Br J Ophthalmol"},{"key":"6878_CR10","doi-asserted-by":"crossref","unstructured":"Tufanaru CMZ, Aromataris E, Campbell J, Hopp L (2020) Systematic reviews of effectiveness: JBI, Available from: https:\/\/synthesismanual.jbi.global","DOI":"10.46658\/JBIRM-17-03"},{"key":"6878_CR11","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"issue":"6","key":"6878_CR12","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/jech.52.6.377","volume":"52","author":"SH Downs","year":"1998","unstructured":"Downs SH, Black N (1998) The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 52(6):377\u2013384","journal-title":"J Epidemiol Community Health"},{"issue":"2","key":"6878_CR13","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/S0002-9394(02)01825-1","volume":"135","author":"RW Beck","year":"2003","unstructured":"Beck RW, Moke PS, Turpin AH, Ferris FL 3rd, SanGiovanni JP, Johnson CA et al (2003) A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol. Am J Ophthalmol 135(2):194\u2013205","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"6878_CR14","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/j.1475-1313.2010.00766.x","volume":"30","author":"B Khoshnood","year":"2010","unstructured":"Khoshnood B, Mesbah M, Jeanbat V, Lafuma A, Berdeaux G (2010) Transforming scales of measurement of visual acuity at the group level. Ophthalmic Physiol Opt 30(6):816\u2013823","journal-title":"Ophthalmic Physiol Opt"},{"key":"6878_CR15","unstructured":"Julian PT, Higgins TL, Deeks JJ (2024) Choosing effect measures and computing estimates of effect. In: Cochrane Handbook for Systematic Reviews of Interventions [Internet]. Available from: https:\/\/training.cochrane.org\/handbook\/current\/chapter-06#section-6-5-2"},{"key":"6878_CR16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T (2014) Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol 14:135","journal-title":"BMC Med Res Methodol"},{"key":"6878_CR17","unstructured":"PlotDigitizer (2025) [3.1.6:[Available from: https:\/\/plotdigitizer.com"},{"issue":"4","key":"6878_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G (2019) How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health 22(4):153\u2013160","journal-title":"Evid Based Ment Health"},{"key":"6878_CR19","doi-asserted-by":"crossref","unstructured":"Kusuhara S, Kishimoto-Kishi M, Matsumiya W, Miki A, Imai H, Nakamura M (2023) Short-Term outcomes of intravitreal faricimab injection for diabetic macular edema. Med (Kaunas) 59(4)","DOI":"10.3390\/medicina59040665"},{"issue":"12","key":"6878_CR20","first-page":"e75002","volume":"16","author":"M Al-Rufayie","year":"2024","unstructured":"Al-Rufayie M, Palmieri F, Hamoud Bedan A, Younis S, Ali A, Kurumthottical M et al (2024) Real-world results in treating diabetic macular edema with faricimab at a London-based tertiary eye hospital. Cureus 16(12):e75002","journal-title":"Cureus"},{"issue":"18","key":"6878_CR21","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1038\/s41433-024-03364-y","volume":"38","author":"GA Borchert","year":"2024","unstructured":"Borchert GA, Kiire CA, Stone NM, Akil H, Gkika T, Fischer MD et al (2024) Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema. Eye (Lond) 38(18):3569\u20133577","journal-title":"Eye (Lond)"},{"key":"6878_CR22","doi-asserted-by":"crossref","unstructured":"Fasler K, Muth DR, Cozzi M, Kvanta A, Rejdak M, Blaser F, Zweifel SA (2024) Dynamics of treatment response to faricimab for diabetic macular edema. Bioeng (Basel) 11(10)","DOI":"10.3390\/bioengineering11100964"},{"issue":"14","key":"6878_CR23","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1167\/iovs.65.14.46","volume":"65","author":"KL Huber","year":"2024","unstructured":"Huber KL, Stino H, Steiner I, Fuchs P, Goldbach F, Mai J et al (2024) Real-world outcomes after switch from aflibercept to faricimab in eyes with diabetic macular edema. Invest Ophthalmol Vis Sci 65(14):46","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6878_CR24","doi-asserted-by":"crossref","unstructured":"Ohara H, Harada Y, Hiyama T, Sadahide A, Minamoto A, Kiuchi Y (2023) Faricimab for diabetic macular edema in patients refractory to ranibizumab or aflibercept. Med (Kaunas) 59(6)","DOI":"10.3390\/medicina59061125"},{"issue":"1","key":"6878_CR25","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s10792-024-03226-2","volume":"44","author":"F Pichi","year":"2024","unstructured":"Pichi F, Abdi A, Aljneibi S, El Ghrably I, Agarwal A, Ghazi NG (2024) Switch to faricimab after initial treatment with aflibercept in eyes with diabetic macular edema. Int Ophthalmol 44(1):275","journal-title":"Int Ophthalmol"},{"key":"6878_CR26","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.2147\/OPTH.S463624","volume":"18","author":"NQX Quah","year":"2024","unstructured":"Quah NQX, Javed K, Arbi L, Hanumunthadu D (2024) Real-world outcomes of faricimab treatment for neovascular age-related macular degeneration and diabetic macular edema. Clin Ophthalmol 18:1479\u20131490","journal-title":"Clin Ophthalmol"},{"key":"6878_CR27","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.2147\/OPTH.S424315","volume":"17","author":"RB Rush","year":"2023","unstructured":"Rush RB (2023) One-year outcomes of faricimab treatment for aflibercept-resistant neovascular age-related macular degeneration. Clin Ophthalmol 17:2201\u20132208","journal-title":"Clin Ophthalmol"},{"key":"6878_CR28","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.2147\/OPTH.S381503","volume":"16","author":"RB Rush","year":"2022","unstructured":"Rush RB, Rush SW (2022) Faricimab for treatment-resistant diabetic macular edema. Clin Ophthalmol 16:2797\u20132801","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"6878_CR29","doi-asserted-by":"publisher","first-page":"13798","DOI":"10.1038\/s41598-024-63435-8","volume":"14","author":"Y Saima","year":"2024","unstructured":"Saima Y, Yokota H, Kushiyama A, Hanaguri J, Ohno A, Takase K et al (2024) Effects of switching from intravitreal injection of aflibercept to faricimab on ocular blood flow in patients with diabetic macular edema. Sci Rep 14(1):13798","journal-title":"Sci Rep"},{"key":"6878_CR30","doi-asserted-by":"publisher","first-page":"8583348","DOI":"10.1155\/2024\/8583348","volume":"2024","author":"SV Savant","year":"2024","unstructured":"Savant SV, Kwan JT, Barouch F, Chang J, Ramsey DJ, Marx J et al (2024) Durability and efficacy of faricimab in treatment-resistant retinal edema utilizing \"real-world\" dosing regimens. J Ophthalmol 2024:8583348","journal-title":"J Ophthalmol"},{"key":"6878_CR31","doi-asserted-by":"crossref","unstructured":"Tatsumi T, Kaiho T, Iwase T, Miura G, Shimizu D, Niizawa T et al (2024) Treatment effects of switching to faricimab in eyes with diabetic macular edema refractory to aflibercept. Med (Kaunas) 60(5)","DOI":"10.3390\/medicina60050732"},{"key":"6878_CR32","doi-asserted-by":"crossref","unstructured":"Wolfrum P, B\u00f6hm EW, Lorenz K, Stoffelns B, Pfeiffer N, Korb CA (2024) Short-term clinical outcomes of patients with diabetic macular edema following a therapy switch to faricimab. J Clin Med 13(15)","DOI":"10.3390\/jcm13154508"},{"issue":"3","key":"6878_CR33","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1001\/jamaophthalmol.2017.6565","volume":"136","author":"NM Bressler","year":"2018","unstructured":"Bressler NM, Beaulieu WT, Glassman AR, Blinder KJ, Bressler SB, Jampol LM et al (2018) Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol 136(3):257\u2013269","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"6878_CR34","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/13543784.2021.1879791","volume":"30","author":"M Nicol\u00f2","year":"2021","unstructured":"Nicol\u00f2 M, Ferro Desideri L, Vagge A, Traverso CE (2021) Faricimab: an investigational agent targeting the Tie-2\/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs 30(3):193\u2013200","journal-title":"Expert Opin Investig Drugs"},{"issue":"8","key":"6878_CR35","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.ophtha.2019.03.023","volume":"126","author":"J Sahni","year":"2019","unstructured":"Sahni J, Patel SS, Dugel PU, Khanani AM, Jhaveri CD, Wykoff CC et al (2019) Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial. Ophthalmology 126(8):1155\u20131170","journal-title":"Ophthalmology"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-06878-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-025-06878-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-06878-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:01:32Z","timestamp":1762160492000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-025-06878-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["6878"],"URL":"https:\/\/doi.org\/10.1007\/s00417-025-06878-7","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]},"assertion":[{"value":"2 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. The study received ethical approval from the Ethics Committee of Tabriz University of Medical Sciences. The manuscript has been read and approved by all the authors and each author believes that the manuscript represents honest work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this research, the authors employed ChatGPT to enhance the clarity and readability of the language. After utilizing this tool, they meticulously examined and adjusted the material as needed, taking complete responsibility for the published work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers\u2019 bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}